Beijing Biostar Technologies, a Chinese developer of anti-tumour, small-molecule chemical drugs, announced on Thursday the completion of a Series E round at 890 million yuan (about $135 million).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
